| Literature DB >> 34880007 |
Deborah Antcliff1,2, Anne-Maree Keenan2,3, Philip Keeley4, Steve Woby5,6, Linda McGowan2.
Abstract
OBJECTIVES: To test the feasibility of using a new activity pacing framework to standardise healthcare professionals' instructions of pacing, and explore whether measures of activity pacing/symptoms detected changes following treatment.Entities:
Keywords: musculoskeletal disorders; pain management; rehabilitation medicine
Mesh:
Year: 2021 PMID: 34880007 PMCID: PMC8655535 DOI: 10.1136/bmjopen-2020-045398
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Activity pacing conceptual model taken from the activity pacing framework.
Participant demographics at baseline (T1)
| Participants who completed T1 but not T2 | Participants who completed T1 and T2 | Total | |
| Gender | (n=42) | (n=65) | (n=107) |
| 6 (14.3%) | 9 (13.8%) | 15 (14.0%) | |
| 36 (85.7%) | 56 (86.2%) | 92 (86.0%) | |
| Age (years) | (n=41) Mean=56.07 | (n=65) Mean=54.74 | (n=106) Mean=55.25 (SD=12.83) |
| Ethnicity | (n=41) | (n=65) | (n=106) |
| 39 (95.1%) | 60 (92.3%) | 99 (93.4%) | |
| 0 (0.0%) | 1 (1.5%) | 1 (0.9%) | |
| 1 (2.4%) | 2 (3.1%) | 3 (2.8%) | |
| 1 (2.4%) | 2 (3.1%) | 3 (2.8%) | |
| 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
| Living situation* | (n=42) | (n=65) | (n=107) |
| 7 (16.7%) | 10 (15.4%) | 17 (15.9%) | |
| 25 (59.5%) | 48 (73.8%) | 73 (68.2%) | |
| 16 (38.1%) | 24 (36.9%) | 40 (37.4%) | |
| 2 (4.8%) | 1 (1.5%) | 3 (2.8%) | |
| Employment | (n=42) | (n=65) | (n=107) |
| 13 (31.0%) | 31 (47.7%) | 44 (41.1%) | |
| 15 (35.7%) | 19 (29.2%) | 34 (31.8%) | |
| 14 (33.3%) | 14 (21.5%) | 28 (26.2%) | |
| 0 (0.0%) | 1 (1.5%) | 1 (0.9%) | |
| Conditions | (n=41) | (n=65) | (n=106) |
| 30 (73.2%) | 49 (75.4%) | 79 (74.5%) | |
| 19 (46.3%) | 33 (50.8%) | 52 (49.1%) | |
| 9 (22.0%) | 20 (30.8%) | 29 (27.4%) | |
| 6 (14.6%) | 6 (9.2%) | 12 (11.3%) | |
| 9 (22.0%) | 12 (18.5%) | 21 (19.8%) | |
| No of the above conditions | (n=41) | (n=65) | (n=106) |
| 17 (41.5%) | 24 (36.9%) | 41 (38.7%) | |
| 19 (46.3%) | 30 (46.2%) | 49 (46.2%) | |
| 3 (7.3%) | 9 (13.8%) | 12 (11.3%) | |
| 1 (2.4%) | 1 (1.5%) | 2 (1.9%) | |
| 1 (2.4%) | 1 (1.5%) | 2 (1.9%) | |
| Duration of participants’ main condition (years) | (n=35) Mean=10.23 | (n=61) Mean=12.94 | (n=96) Mean=11.95 (SD=10.74) |
*Patients could select more than one answer.
CFS/ME, chronic fatigue syndrome/myalgic encephalomyelitis.
Baseline scores for activity pacing and symptoms for all patients completing the baseline questionnaires (T1)
| Measures (range of scores) | Baseline scores for those completed T1 but not T2: | Baseline scores for those completed T1 and T2: | Total scores |
| APQ-28 activity adjustment (0–4) | (n=42) 1.96 (0.87) | (n=64) 1.74 (0.76) | (n=106) 1.83 (0.81) |
| APQ-28 activity planning (0–4) | (n=42) 1.57 (1.03) | (n=65) 1.44 (0.95) | (n=107) 1.49 (0.98) |
| APQ-28 activity consistency (0–4) | (n=42) 1.91 (0.91) | (n=65) 1.82 (0.96) | (n=107) 1.85 (0.94) |
| APQ-28 activity acceptance (0–4) | (n=42) 1.97 (1.02) | (n=65) 1.87 (0.84) | (n=107) 1.91 (0.92) |
| APQ-28 activity progression (0–4) | (n=42) 1.59 (1.05) | (n=65) 1.45 (0.88) | (n=107) 1.51 (0.95) |
| Current pain (0–10) | (n=41) 6.83 (1.96) | (n=65) 6.63 (1.97) | (n=106) 6.71 (1.96) |
| Usual pain (0–10) | (n=40) 7.72 (1.43) | (n=63) 7.30 (1.82) | (n=103) 7.47 (1.69) |
| Physical fatigue (7-28) | (n=41) 14.18 (5.12) | (n=62) 15.22 (4.10) | (n=103) 14.81 (4.54) |
| Mental fatigue (4-16) | (n=42) 8.79 (3.22) | (n=64) 8.86 (2.77) | (n=106) 8.83 (2.94) |
| Depression (0–27) | (n=40) 12.63 (7.61) | (n=64) 13.66 (6.38) | (n=104) 13.26 (6.86) |
| Anxiety (0–21) | (n=41) 9.86 (6.64) | (n=65) 9.91 (5.47) | (n=106) 9.89 (5.92) |
| Self-efficacy (0–60) | (n=42) 26.26 (13.85) | (n=65) 25.29 (10.60) | (n=107) 25.67 (11.93) |
| Avoidance (0–25) | (n=42) 12.95 (6.74) | (n=64) 13.27 (5.49) | (n=106) 13.14 (5.98) |
| Physical function (0–100) | (n=42) 33.67 (9.75) | (n=63) 34.15 (8.23) | (n=105) 33.96 (8.82) |
| Mental function (0–100) | (n=42) 42.22 (11.51) | (n=63) 38.52 (11.10) | (n=105) 40.00 (11.36) |
| Quality of life (0–1) | (n=40) 0.41 (0.26) | (n=60) 0.43 (0.25) | (n=100) 0.42 (0.25) |
Activity pacing (APQ-28), Pain (Numerical Rating Scale 0–10), Physical/mental fatigue (Chalder Fatigue Questionnaire), Depression (Patient Health Questionnaire-9), Anxiety (Generalised Anxiety Disorder-7), Self-efficacy (Pain Self-Efficacy Questionnaire), Avoidance (Escape and avoidance subscale of the Pain Anxiety Symptoms Scale-20), Physical/mental function (Short-Form 12), Quality of life (EQ-5D-5L EuroQol five-dimensions, five-levels index score).
APQ-28, 28-item Activity Pacing Questionnaire.
Figure 2CONSORT diagram showing the flow of participants through the study. CONSORT, Consolidated Standards of Reporting Trials.
Figure 3Participants’ written comments following attending the rehabilitation programme.
Mean changes in the five subthemes of activity pacing (APQ-28) between T1 (baseline), T2 (end of 6 weeks’ treatment) and T3 (3 months’ follow-up)
| Measures | T1 mean (SD) | T2-T1 mean change (95% CI); effect size(d) | T2 mean (SD) | T3-T2 mean change (95% CI); effect size(d) | T3 mean | T3-T1 mean change (95% CI); effect size(d) |
| APQ-28 activity adjustment | (n=63) | 0.70 (95% CI=0.48 to 0.91); d=0.91 | (n=51) | −0.12 (95% CI= −0.36 to 0.11); d=−0.17 | (n=50) | 0.58 (95% CI=0.33 to 0.83); d=0.74 |
| APQ-28 activity planning | (n=65) | 0.99 (95% CI=0.72 to 1.26); d=1.03 | (n=52) | −0.39 (95% CI= −0.70 to −0.07); d=−0.45 | (n=52) | 0.64 (95% CI=0.36 to 0.92); d=0.67 |
| APQ-28 activity consistency | (n=65) | 0.84 (95% CI=0.60 to 1.07); d=0.86 | (n=52) | −0.29 (95% CI= −0.54 to −0.04); d=−0.41 | (n=52) | 0.51 (95% CI=0.24 to 0.78); d=0.51 |
| APQ-28 activity acceptance | (n=65) | 0.67 (95% CI=0.46 to 0.89); d=0.81 | (n=52) | −0.15 (95% CI= −0.38 to 0.08); d=−0.21 | (n=52) | 0.58 (95% CI=0.33 to 0.84); d=0.64 |
| APQ-28 activity progression | (n=65) | 0.94 (95% CI=0.65 to 1.22); d=1.07 | (n=52) | −0.40 (95% CI= −0.75 to −0.05); d=−0.44 | (n=52) | 0.56 (95% CI=0.24 to 0.87); d=0.65 |
APQ-28, 28-item Activity Pacing Questionnaire.
Mean changes in measures of symptoms between T1 (baseline), T2 (end of 6 weeks’ treatment) and T3 (3 months’ follow-up)
| Measures | T1 mean (SD) | T2-T1 mean change (95% CI); effect size(d) | T2 mean (SD) | T3-T2 mean change (95% CI); effect size(d) | T3 mean | T3-T1 mean change (95% CI); effect size(d) |
| Current pain | (n=65) | −1.32 (95% CI= −1.91 to −0.74); d=−0.67 | (n=52) | 0.62 (95% CI=−0.08 to 1.31); d=0.26 | (n=52) | −0.92 (95% CI= −1.58 to −0.27); d=−0.47 |
| Usual pain | (n=65) | −0.68 (95% CI= −1.19 to −0.18); d=−0.37 | (n=51) | 0.02 (95% CI=−0.48 to 0.52); d=0.01 | (n=50) | −0.76 (95% CI= −1.27 to −0.25); d=−0.47 |
| Physical fatigue | (n=62) | 5.08 (95% CI=3.95 to 6.21); d=1.24 | (n=51) | −2.35 (95% CI= −3.44 to −1.26); d=−0.57 | (n=49) | 2.84 (95% CI=1.34 to 4.33); d=0.73 |
| Mental fatigue | (n=64) | 2.42 (95% CI=1.75 to 3.10); d=0.87 | (n=51) | −0.53 (95% CI= −1.17 to 0.11); d=−0.24 | (n=51) | 1.98 (95% CI=1.33 to 2.64); d=0.79 |
| Depression | (n=63) | −6.51 (95% CI= −7.72 to −5.31); d=−1.01 | (n=51) | 2.96 (95% CI=1.64 to 4.29); d=0.54 | (n=51) | −4.09 (95% CI= −5.61 to −2.57); d=−0.64 |
| Anxiety | (n=65) | −4.51 (95% CI= −5.60 to −3.42); d=−0.82 | (n=52) | 1.44 (95% CI=0.55 to 2.33); d=0.32 | (n=52) | −3.37 (95% CI= −4.63 to −2.12); d=−0.67 |
| Self-efficacy | (n=65) | 11.00 (95% CI=8.44 to 13.56); d=1.04 | (n=52) | −3.28 (95% CI= −7.17 to 0.60); d=−0.23 | (n=52) | 8.83 (95% CI=5.86 to 11.81); d=0.82 |
| Avoidance | (n=64) | −2.98 (95% CI= −4.43 to −1.54); d=−0.54 | (n=52) | 1.27 (95% CI=−0.27 to 2.81); d=0.21 | (n=52) | −1.46 (95% CI= −3.02 to 0.10); d=−0.26 |
| Physical function | (n=63) | 4.67 (95% CI=2.69 to 6.65); d=0.57 | (n=49) | −2.82 (95% CI= −5.29 to −0.35); d=−0.32 | (n=47) | 1.62 (95% CI=−0.81 to 4.06); d=0.20 |
| Mental function | (n=63) | 7.30 (95% CI=4.49 to 10.12); d=0.66 | (n=49) | −1.97 (95% CI= −5.22 to 1.29); d=−0.18 | (n=47) | 5.95 (95% CI=2.83 to 9.08); d=0.56 |
| Quality of life | (n=59) | 0.13 (95% CI=0.07 to 0.18); d=0.52 | (n=48) | −0.09 (95% CI= −0.14 to −0.03); d=−0.36 | (n=45) | 0.07 (95% CI=0.001 to 0.14); d=0.29 |
Pain (Numerical Rating Scale 0–10), Physical/mental fatigue (Chalder Fatigue Questionnaire), Depression (Patient Health Questionnaire-9), Anxiety (Generalised Anxiety Disorder-7), Self-efficacy (Pain Self-Efficacy Questionnaire), Avoidance (Escape and avoidance subscale of the Pain Anxiety Symptoms Scale-20), Physical/mental function (Short-Form 12), Quality of life (EQ-5D-5L EuroQol five-dimensions, five levels index score).